In a report released on September 23, Arsene Guekam from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), with a price target of EUR3.10. The company’s shares closed last Wednesday at $2.57.
According to TipRanks, Guekam is an analyst with an average return of -4.1% and a 27.11% success rate. Guekam covers the Healthcare sector, focusing on stocks such as Adocia SA, Innate Pharma SA, and Genfit.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Innate Pharma SA with a $4.94 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $7.06 and a one-year low of $2.13. Currently, Innate Pharma SA has an average volume of 890.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells. The company was founded by Hervé Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié and François Romagné on September 15, 1999 and is headquartered in Marseille, France.
